Recent developments include clinical trial progress, regulatory designations, and financial results reflecting narrowing losses and ongoing development activities.

• Lantern Pharma reported Q1 2025 earnings with detailed clinical and financial updates [N1].
• The company’s Q4 net loss narrowed, and a Type C meeting with the FDA for LP-300 was scheduled for mid-May 2026 [N2].
• Lantern Pharma shares rose following positive market and clinical news [N3].
• The stock fell 10% after FDA cleared an investigational new drug application for STAR-001, reflecting market sensitivity to regulatory news [N4].
• Lantern Pharma received FDA orphan drug designation for LP-284, supporting regulatory exclusivity [N5].
• Positive Phase 1a data for LP-184 in advanced solid tumors was reported, meeting all primary endpoints [N6][N7].
• The company reported positive Phase 2 HARMONIC study results in 'never smokers' with NSCLC [N8].
• Lantern Pharma narrowed its loss in Q2 2025, indicating progress in financial management [N8].

The company’s use of AI and genomics to identify and develop oncology drug candidates represents a novel approach that could streamline drug development and improve targeting of therapies. Positive clinical trial results and orphan drug designations indicate progress in advancing its pipeline. Engagements with the FDA, including Type C meetings, demonstrate active regulatory strategy. The company’s liquidity position supports continued development activities. If clinical and regulatory milestones are met, Lantern Pharma could establish a differentiated position in precision oncology therapeutics.

Lantern Pharma operates in a highly competitive and risky biotech environment with no approved products and ongoing net losses. Clinical trial outcomes remain uncertain, and regulatory approvals are not guaranteed. The company’s liquidity, while sufficient for current operations, may require additional financing, which could dilute shareholders. Market reactions to clinical and regulatory news have shown volatility. The reliance on AI and genomics, while innovative, may face challenges in validation and adoption. Execution risks include clinical development delays, regulatory setbacks, and competitive pressures.

Lantern Pharma’s moat is based on its integration of AI and genomics to develop precision oncology therapeutics, which may provide a competitive edge in identifying and advancing drug candidates. The company’s orphan drug designations and positive clinical data support potential regulatory exclusivities and market differentiation. Additionally, the experienced management team with backgrounds in biotech innovation and regulatory affairs contributes to execution capability. However, as a clinical-stage company without approved products, the moat is contingent on successful clinical development and regulatory approvals.

• Clinical Development Risk: The company’s drug candidates are in early clinical stages, and there is inherent uncertainty in achieving successful trial outcomes and regulatory approvals.
• Regulatory Risk: Interactions with the FDA and other regulatory bodies may result in delays, additional requirements, or denials impacting development timelines.
• Financial Risk: Lantern Pharma reports ongoing net losses and relies on available cash and investments to fund operations; future capital needs may lead to dilution or financing challenges.
• Market and Competitive Risk: The oncology therapeutics market is highly competitive with many established and emerging players; success depends on differentiation and clinical validation.

• Lantern Pharma Inc. is a clinical-stage oncology company focused on developing precision therapeutics using AI and genomics to innovate cancer treatments [S1].
• The company has a pipeline including drug candidates LP-184, LP-284, LP-300, and STAR-001, with various stages of clinical trials and regulatory interactions [N1][N2][N4][N5].
• Lantern Pharma received FDA orphan drug designation for LP-284 [N5].
• The company reported positive Phase 1a data for LP-184 in advanced solid tumors, meeting all primary endpoints [N6][N7].
• Lantern Pharma reported positive results from a Phase 2 HARMONIC study in 'never smokers' with non-small cell lung cancer (NSCLC) [N8].
• The company has engaged with the FDA for a Type C meeting regarding LP-300, scheduled for mid-May 2026 [N2].
• Lantern Pharma’s stock price has shown volatility in response to clinical and regulatory news, including a 10% drop after FDA cleared an investigational new drug application for STAR-001 [N4].
• As of June 30, 2026, Lantern Pharma had cash and cash equivalents of approximately $6.66 million, short-term investments of $0.7 million, current assets of $8.46 million, and current liabilities of $4.32 million, resulting in a current ratio of 1.96 and a cash ratio of 1.7 [S2].
• The company reported a net loss of approximately $7.07 million and basic and diluted EPS of -$0.57 for the quarter ended June 30, 2026 [S2].
• Lantern Pharma had approximately 11.3 million shares outstanding as of April 29, 2026, with a market value of non-affiliate shares around $33.9 million [S1].
• The executive team includes CEO Panna Sharma, CFO David R. Margrave, CSO Kishor G. Bhatia, and Chairman Donald Jeff Keyser, with detailed backgrounds in biotech, finance, and regulatory affairs [S1].